Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Schmid, Peter, Adams, Sylvia, Rugo, Hope S., Schneeweiss, Andreas, Barrios, Carlos H., Iwata, Hiroji, Diéras, Véronique, Hegg, Roberto, Im, Seock-Ah, Shaw Wright, Gail, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y., Funke, Roel, Husain, Amreen, Winer, Eric P., Loi, Sherene, Emens, Leisha A.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1809615

Cited by (1,010)

Items 101–200 of 1,010

Immunotherapy in breast cancer: an overview of current strategies and perspectives
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, Martine J Piccart, Vincent K. Tuohy, Emanuela Romano, Laurence Buisseret · 2023 · npj Breast Cancer
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Özge Saatci, Aysegül Kaymak, Umar Raza, Pelin Gulizar Ersan, Özge Akbulut, Carolyn E. Banister, Vitali Sikirzhytski, Ünal Metin Tokat, Gamze Aykut, Suhail A. Ansari et al. · 2020 · Nature Communications
Towards targeting the breast cancer immune microenvironment
Michael A. Harris, Peter Stephen Savas, Balaji Virassamy, Megan M. R. O’Malley, Jasmine Kay, Scott N. Mueller, Laura K. Mackay, Roberto Salgado, Sherene Loi · 2024 · Nature reviews. Cancer
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Romualdo Barroso‐Sousa, Esha Jain, Ofir Cohen, D. Kim, Jorge E. Buendia-Buendia, Eric P. Winer, NU Lin, Sara M. Tolaney, Nikhil Wagle · 2020 · Annals of Oncology
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao, Ding Ma, Shen Zhao, Chen Suo, Jinxiu Shi, Mengzhu Xue, Miao Ruan, Hai Wang, Jingjing Zhao, Qin Li et al. · 2019 · Clinical Cancer Research
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra, Giulia Viale, Giuseppe Curigliano · 2019 · BMC Medicine
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng, Qi Li, Nong Xu, Xichun Hu, Wangjun Liao, Yi Jiang, Xiaoyan Lin, Qingyuan Zhang et al. · 2021 · Journal of Clinical Oncology
Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
Zhang, Qu, Luo, Jia, Wu, Song, Si, Han, Gao, Chen, Xu, Wenjing, Abdullah, Shaad E., Higgs, Brandon W., Dennis, Phillip A., van der Heijden, Michiel S. et al. · 2020 · Cancer Discovery
Advances in immunotherapy for triple-negative breast cancer
Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Yi Jiang, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu · 2023 · Molecular Cancer
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu · 2023 · Journal of Hematology & Oncology
Tumor-associated macrophages: an effective player of the tumor microenvironment
Udit Basak, Tania Sarkar, Sumon Mukherjee, Sourio Chakraborty, Apratim Dutta, Saikat Dutta, Debadatta Nayak, Subhash Kaushik, Tanya Das, Gaurisankar Sa · 2023 · Frontiers in Immunology
Targeting the PI3-kinase pathway in triple-negative breast cancer
Javier Pascual, Nicholas C. Turner · 2019 · Annals of Oncology
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Gagan K. Gupta, Amber L. Collier, Dasom Caroline Lee, Richard A. Hoefer, Vasilena P. Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston et al. · 2020 · Cancers
Development of Immunotherapy Combination Strategies in Cancer
Timothy Anthony Yap, Eileen E. Parkes, Weiyi Peng, Justin Tyler Moyers, Michael A. Curran, Hussein A. Tawbi · 2021 · Cancer Discovery
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Kailin Yang, Ahmed Halima, Timothy An-thy Chan · 2023 · Nature Reviews Clinical Oncology
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Antonio Marra, Dario Trapani, Giulia Viale, Carmen Criscitiello, Giuseppe Curigliano · 2020 · npj Breast Cancer
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche
Pilar Baldominos, Alex Barbera-Mourelle, Olga Barreiro, Yu Huang, Andrew E. Wight, Jae-Won Cho, Xi Zhao, Guillem Estivill, Isam Adam, Xavier Sanchez et al. · 2022 · Cell
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Fernanda Mosele, Bojana Stefanovska, Amélie Lusque, Alicia Tran Dien, Ingrid Garberis, Nathalie M Droin, Christophe Le Tourneau, Marie‐Paule Sablin, Ludovic Lacroix, Diego Hernán Enrico et al. · 2020 · Annals of Oncology
Targeted Therapies for Triple-Negative Breast Cancer
Tomás G. Lyons · 2019 · Current Treatment Options in Oncology
Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy
Weidi Yu, Guan Sun, Jun Li, Xu Jiang, Xiaochen Wang · 2019 · Cancer Letters
Pathology of triple negative breast cancer
Filippo Borri, Annarita Granaglia · 2020 · Seminars in Cancer Biology
Atezolizumab and nab -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens, Luciana Lorena Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Veronique C Dieras, Hiroji Iwata, Carlos H. Barrios, Marina N. Nechaeva, Anh Nguyen-Duc et al. · 2021 · JNCI Journal of the National Cancer Institute
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Davide Ciardiello, Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello · 2019 · Cancer Treatment Reviews
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, Michael J. Birrer, Leslie M. Randall, Elena V Poddubskaya, Giovanni Scambia, Yaroslav V. Shparyk, Myong Cheol Lim et al. · 2021 · The Lancet Oncology
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Ann Byrne, Peter Stephen Savas, Sneha Ashok Sant, Ran Li, Balaji Virassamy, Stephen James Luen, Paul A. Beavis, Laura K. Mackay, Paul Joseph Neeson, Sherene Loi · 2020 · Nature Reviews Clinical Oncology
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Matthew Gerard Davey, Seán O. Hynes, Michael Joseph Kerin, Nicola Miller, Aoïfe Lowery · 2021 · Cancers
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Hack, Stephen P., Zhu, Andrew X., Wang, Yulei · 2020 · Frontiers in Immunology
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
Yi-Zhou Jiang, Yin Liu, Yi Xiao, Xin Hu, Lin Jiang, Wen‐Jia Zuo, Ding Ma, Jia-Han Ding, Xiaoyu Zhu, Jianjun Zou et al. · 2020 · Cell Research
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie C. Postel-Vinay · 2021 · Nature reviews. Cancer
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Marie Kostine, Axel Finckh, Clifton O. Bingham, Karen Visser, Jan Leipe, Hendrik Schulze‐Koops, Ernest Choy, Karolina Benesova, Timothy R. D. J. Radstake, Andrew P. Cope et al. · 2020 · Annals of the Rheumatic Diseases
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Conforti, Fabio, Pala, Laura, Bagnardi, Vincenzo, Viale, Giuseppe, De Pas, Tommaso, Pagan, Eleonora, Pennacchioli, Elisabetta, Cocorocchio, Emilia, Ferrucci, Pier Francesco, De Marinis, Filippo et al. · 2019 · JNCI: Journal of the National Cancer Institute
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Xupeng Bai, Jie Ni, Julia Beretov, Peter Graham, Yong Li · 2020 · Cancer Letters
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, Rezvan, Bayat, Payam, Oroojalian, Fatemeh, Zargari, Mehryar, Ramezani, Mohammad, Taghdisi, Seyed Mohammad, Abnous, Khalil · 2020 · International Journal of Biological Macromolecules
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
Jin‐Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiaojie Lu, Jiansong Ji · 2020 · Biomarker Research
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner · 2023 · Nature Reviews Clinical Oncology
Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity
Yiwen Lu, Qiyi Zhao, Jian‐You Liao, Erwei Song, Qidong Xia, Jiayao Pan, Yihong Li, Jiaqian Li, Boxuan Zhou, Yingying Ye et al. · 2020 · Cell
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita Kuldeep Mehta, Emily M. Cheney, Christina Hartl, Constantia Pantelidou, Madisson Oliwa, Jessica C. Lal, Jia‐Ren Lin, Katie E. Hurst, Mateus de Oliveira Taveira, Nathan T. Johnson et al. · 2020 · Nature Cancer
The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer
Yutian Zou, Feng Ye, Yanan Kong, Xiaoqian Hu, Xinpei Deng, Jindong Xie, Cailu Song, Xueqi Ou, Song Wu, Linyu Wu et al. · 2022 · Advanced Science
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis
Markus Kuksis, Yizhuo Kelly Gao, William T. Tran, Christianne Hoey, Alex Kiss, Adam S. Komorowski, Aman J Dhaliwal, Arjun Sahgal, Sunit Das, Kelvin Chan et al. · 2020 · Neuro-Oncology
Probiotic-guided CAR-T cells for solid tumor targeting
Vincent, Rosa L., Gurbatri, Candice R., Li, Fangda, Vardoshvili, Ana, Coker, Courtney, Im, Jongwon, Ballister, Edward R., Rouanne, Mathieu, Savage, Thomas, de los Santos-Alexis, Kenia et al. · 2023 · Science
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael Joe Duffy, John Paul Crown · 2019 · Clinical Chemistry
Pembrolizumab and atezolizumab in triple-negative breast cancer
Dorota Malgorzata Kwapisz · 2020 · Cancer Immunology Immunotherapy
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Khalid El Bairi, Harry R. Haynes, Elizabeth F. Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Genel Sur, Luis Claudio Amendola, Masoumeh Gharib et al. · 2021 · npj Breast Cancer
Management of Male Breast Cancer: ASCO Guideline
Michael J. Hassett, Mark R. Somerfield, Elisha Baker, Fátima Cardoso, Kari Joanne Kansal, Dylan C. Kwait, Jennifer Kay Plichta, Charite Nicolette Ricker, Anna Roshal, Kathryn J. Ruddy et al. · 2020 · Journal of Clinical Oncology
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Sibylle Loibl, Andreas Schneeweiß, Jens Huober, Michael Braun, Julia Rey, Jens‐Uwe Blohmer, Jenny Furlanetto, D M Zahm, Claus Alexander Hanusch, Jörg Thomalla et al. · 2022 · Annals of Oncology
Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
Kha‐Liang Lee, Yung‐Che Kuo, Yuan‐Soon Ho, Yen‐Hua Huang · 2019 · Cancers
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options
Jae Young So, Joyce Ellen Ohm, Stan Lipkowitz, Yang Li · 2022 · Pharmacology & Therapeutics
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Moumita Kundu, Ramesh Butti, Venketesh K. Panda, Diksha Malhotra, Sumit Das, Tandrima Mitra, Prachi Kapse, Suresh Gosavi, Gopal C. Kundu · 2024 · Molecular Cancer
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
María Ochoa de Olza, Blanca Navarro Rodrigo, Stefan Zimmermann, George Coukos · 2020 · The Lancet Oncology
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Zhen-Duo, Pang, Kun, Wu, Zhuo-Xun, Dong, Yang, Hao, Lin, Qin, Jia-Xin, Wang, Wei, Chen, Zhe-Sheng, Han, Cong-Hui · 2023 · Signal Transduction and Targeted Therapy
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
Xiaoxiang Zhou, Zhuoran Yao, Hua Bai, Jianchun Duan, Zhijie Wang, Xin Wang, Xue Zhang, Jiachen Xu, Kailun Fei, Zhen Zhang et al. · 2021 · The Lancet Oncology
Nanomaterials in tumor immunotherapy: new strategies and challenges
Xudong Zhu, Shenglong Li · 2023 · Molecular Cancer
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy
Vincenzo Salemme, Giorgia Centonze, Federica Cavallo, Paola Defilippi, Laura Conti · 2021 · Frontiers in Oncology
Triple-negative breast cancer: recent treatment advances
Alice R.T. Bergin, Sherene Loi · 2019 · F1000Research
Progress and challenges of immunotherapy in triple-negative breast cancer
Yinxing Zhu, Xuedan Zhu, Cuiju Tang, Xiaoxiang Guan, Wenwen Zhang · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
Elizabeth C. Paver, Wendy A. Cooper, Andrew J. Colebatch, Peter M. Ferguson, Sean K. Hill, Trina Lum, Joo‐Shik Shin, Sandra A. O’Toole, Lyndal A. Anderson, Richard A. Scolyer et al. · 2020 · Pathology
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Chong-xian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li, Lei Zheng · 2020 · Journal of Hematology & Oncology
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Jasmine Singh Sukumar, Kelly C. Gast, Dionisia Marie Quiroga, Maryam B. Lustberg, Nicole Olivia Williams · 2020 · Expert Review of Anticancer Therapy
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Jean-David Fumet, Caroline Truntzer, Mark M. Yarchoan, François Ghiringhelli · 2020 · European Journal of Cancer
Biomimetic Diselenide‐Bridged Mesoporous Organosilica Nanoparticles as an X‐ray‐Responsive Biodegradable Carrier for Chemo‐Immunotherapy
Dan Shao, Fan Zhang, Fangman Chen, Xiao Zheng, Hanze Hu, Chao Yang, Zhaoxu Tu, Zheng Wang, Zhimin Chang, Junna Lu et al. · 2020 · Advanced Materials
Treatment strategies for breast cancer brain metastases
Caroline Bailleux, Lauriane Eberst, Thomas Bachelot · 2020 · British Journal of Cancer
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Majidpoor, Jamal, Mortezaee, Keywan · 2021 · Clinical Immunology
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
Balaji Virassamy, Franco Caramia, Peter Stephen Savas, Sneha Ashok Sant, Jianan Wang, Susan N. Christo, Ann Byrne, Kylie A. Clarke, Emmaline Brown, Zhi Ling Teo et al. · 2023 · Cancer Cell
Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1
Yun Zhao, Zhongshun Liu, Guoqiang Liu, Yuting Zhang, Sheng Liu, Dailin Gan, Wennan Chang, Xiaoxia Peng, Eun Suh Sung, Keegan Gilbert et al. · 2023 · Cell Metabolism
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Maria Vittoria Dieci, Federica Miglietta, Valentina Guarneri · 2021 · Cells
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
Sylvie Lorenzen, Thorsten Oliver Götze, Peter C Thuss-Patience, Matthias Biebl, Nils Homann, Michael Schenk, Udo Lindig, Vera Heuer, Albrecht Kretzschmar, Eray Goekkurt et al. · 2023 · Journal of Clinical Oncology
Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants
Sumit Siddharth, Dipali Sharma · 2018 · Cancers
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Thomas Karn, Carsten Denkert, Karsten Ernst Weber, Uwe Holtrich, Claus Alexander Hanusch, Bruno Valentin Sinn, Brandon W. Higgs, Paul Jank, Hans‐Peter Sinn, Jens Huober et al. · 2020 · Annals of Oncology
Future Directions in the Treatment of Osteosarcoma
Alannah Smrke, Peter Meade Anderson, Ashish Gulia, Spyridon Gennatas, Paul H. Huang, Robin L. Jones · 2021 · Cells
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier, Anthony Gonçalvès · 2019 · Cancers
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
Bridget P. Keenan, Lawrence H. Fong, Robin Kate Kelley · 2019 · Journal for ImmunoTherapy of Cancer
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Barèche, Laurence Buisseret, Tina Gruosso, Edwina Girard, David Venet, Floriane Dupont, Christine Desmedt, Denis Larsimont, Morag Park, Françoise Rothé et al. · 2019 · JNCI Journal of the National Cancer Institute
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
Archis Bagati, Sushil Kumar, Peng Jiang, Jason W. Pyrdol, Angela E. Zou, Anže Godicelj, Nathan D. Mathewson, Adam N.R. Cartwright, Paloma Cejas, Myles A Brown et al. · 2020 · Cancer Cell
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Cristina Birzu, Pim J. French, Mario Caccese, Giulia Cerretti, Ahmed Idbaïh, Vittorina Zagonel, Giuseppe Lombardi · 2020 · Cancers
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes
Sayali Onkar, Neil M. Carleton, Peter C. Lucas, Tullia Carmela Bruno, Adrian V. Lee, Dario A.A. Vignali, Steffi Oesterreich · 2022 · Cancer Discovery
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
Karama Asleh, Nazia Riaz, Torsten O. Nielsen · 2022 · Journal of Experimental & Clinical Cancer Research
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
Maroun Bou Zerdan, Tala Ghorayeb, Fares Saliba, Sabine Allam, Morgan Bou Zerdan, Marita Yaghi, Nadeem Bilani, Rola F. Jaafar, Zeina A. Nahleh · 2022 · Cancers
Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics
Rishav Kar, Rajib Dhar, Sayantanee Mukherjee, Sagnik Nag, Sukhamoy Gorai, Nobendu Mukerjee, Dattatreya Mukherjee, Rishabh Vatsa, Mamtha Jadhav, Arabinda Ghosh et al. · 2023 · ACS Biomaterials Science & Engineering
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Paula I. González Ericsson, Elisabeth Specht Stovgaard, Luz Fernanda Sua, Emily Reisenbichler, Zuzana Kos, Jodi M. Carter, Stefan Michiels, John P. C. Le Quesne, Torsten O. Nielsen, Anne‐Vibeke Lænkholm et al. · 2020 · The Journal of Pathology
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
Takayuki Iwamoto, Naoki Niikura, Rin Ogiya, Hiroyuki Yasojima, Kenichi Watanabe, Chizuko Kanbayashi, Michiko Tsuneizumi, Akira Matsui, Tomomi Fujisawa, Tsutomu Iwasa et al. · 2019 · Scientific Reports
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
Cecilia Roux, Soode Moghadas Jafari, Rahul Suresh Shinde, Gordon S. Duncan, David W. Cescon, Jennifer Silvester, Mandy F. Chu, Kelsey Hodgson, Thorsten Berger, Andrew C. Wakeham et al. · 2019 · Proceedings of the National Academy of Sciences
If we build it they will come: targeting the immune response to breast cancer
Margaret Elena Gatti-Mays, Justin Micah Balko, Sofia R. Gameiro, Harry D. Bear, Sangeetha Prabhakaran, Jami Aya Fukui, Mary Lenora Disis, Rita Nanda, James L. Gulley, Kevin M. Kalinsky et al. · 2019 · npj Breast Cancer
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
Masanori Oshi, Yoshihisa Tokumaru, Mariko Asaoka, Li Yan, Vikas Satyananda, Ryusei Matsuyama, Nobuhisa Matsuhashi, Manabu Futamura, Takashi Ishikawa, Kazuhiro Yoshida et al. · 2020 · Scientific Reports
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target
Xiaoqing Wang, Collin J. Tokheim, Shengqing Stan Gu, Binbin Wang, Qin Tang, Yihao Li, Nicole C. Traugh, Zexian Zeng, Yi Zhang, Ziyi Li et al. · 2021 · Cell
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, Shaojie Jiang · 2022 · Journal of Hematology & Oncology
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martín, Hope S. Rugo, Veronique C Dieras, Seock‐Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui Ray Lu et al. · 2019 · Clinical Cancer Research
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas, Ghaneya Al‐Khadairi, Julie V. Decock · 2021 · Frontiers in Oncology
Exosomes and breast cancer drug resistance
Xingli Dong, Xupeng Bai, Jie Ni, Hao Zhang, Wei Duan, Peter Graham, Yong Li · 2020 · Cell Death and Disease
Recent advances in nanotheranostics for triple negative breast cancer treatment
Vikram Thakur, Rajaletchumy Veloo Kutty · 2019 · Journal of Experimental & Clinical Cancer Research
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Paul M Hofman, Simon Heeke, Catherine Alix‐Panabières, Klaus Pantel · 2019 · Annals of Oncology
An innate-like Vδ1 + γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Yin Wu, Fernanda Kyle‐Cezar, Richard Woolf, Cristina Naceur‐Lombardelli, Julie Owen, Dhruva Biswas, Anna Lorenc, Pierre Vantourout, Patrycja Gazińska, Anita E. Grigoriadis et al. · 2019 · Science Translational Medicine
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
Alice Y. Ho, Christopher Andrew Barker, Brittany B. Arnold, Simon N. Powell, Zishuo I. Hu, Ayca Gucalp, Lizza Lebron‐Zapata, Hannah Yong Wen, Cindy E. Kallman, Alessandro D’Agnolo et al. · 2019 · Cancer
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance
Shen Zhao, Ding Ma, Yi Xiao, Xiaomei Li, Jianli Ma, Han Zhang, Xiaoli Xu, Hong Lv, Wenhua Jiang, Wen-Tao Yang et al. · 2020 · The Oncologist
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, Rodion A. Velichinskii, Randy W. Lesh, Usman Ali, Michal Jakub Kubiak, Pranshu Bansal, Hossein Borghaei, Martin Joseph Edelman, Yanis Boumber · 2019 · Advances in Therapy
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
Nader El-Sayes, Alyssa Vito, Karen Louise Mossman · 2021 · Cancers
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
Ying‐Nai Wang, Heng‐Huan Lee, Jennifer L. Hsu, Dihua Yu, Mien‐Chie Hung · 2020 · Journal of Biomedical Science
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
Leitao Sun, Leyin Zhang, Jieru Yu, Yinan Zhang, Xi Pang, Chenghao Ma, Minhe Shen, Shanming Ruan, Harpreet Singh Wasan, Shengliang Qiu · 2020 · Scientific Reports
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes
Nikolaos Zacharakis, Lutfi Huq, Samantha J. Seitter, Sanghyun Peter Kim, Jared J. Gartner, Sivasish Sindiri, Victoria K. Hill, Yong F. Li, Biman C. Paria, Satyajit Ray et al. · 2022 · Journal of Clinical Oncology
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Yeon Hee Park, Samir Lal, Jeong Eon Lee, Yoon‐La Choi, Ji Wen, Sripad Ram, Ying Ding, Soo Hyun Lee, Eric L. Powell, Se Kyung Lee et al. · 2020 · Nature Communications